<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37604638</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e003302</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2023-003302</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable background therapy. Topics of special interest included infections and cardiovascular and thromboembolic events.</AbstractText><AbstractText Label="METHODS">This analysis included integrated safety data from three randomised, placebo-controlled studies (one phase 2 and two phase 3) and one long-term extension study. Data are reported in three data sets: placebo-controlled, extended exposure and all-baricitinib. Outcomes include treatment-emergent adverse events (AEs), AEs of special interest and abnormal laboratory changes. Proportions of patients with events and incidence rates (IRs) were calculated.</AbstractText><AbstractText Label="RESULTS">A total of 1655 patients received baricitinib for up to 3.5 years (median duration 473 days). With baricitinib 4&#x2009;mg, baricitinib 2&#x2009;mg and placebo, respectively, 50.8%, 50.7% and 49.0% of patients reported at least one infection and 4.4%, 3.4% and 1.9% of patients had a serious infection. The most common treatment-emergent infections included urinary tract infection, COVID-19, upper respiratory tract infection and nasopharyngitis. Herpes zoster was more common with baricitinib 4&#x2009;mg (4.7%) vs baricitinib 2&#x2009;mg (2.7%) and placebo (2.8%). Among baricitinib-4 mg, 2&#x2009;mg and placebo-treated patients, respectively, 4 (IR=0.9), 1 (IR=0.2) and 0 experienced at least one positively adjudicated major adverse cardiovascular event, and 0, 3 (IR=0.6) and 2 (IR=0.4) reported at least one positively adjudicated venous thromboembolism.</AbstractText><AbstractText Label="CONCLUSIONS">The results of this integrated safety analysis in patients with SLE are not substantially different to the established safety profile of baricitinib. No increased venous thromboembolism was found.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morand</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9507-3338</Identifier><AffiliationInfo><Affiliation>Centre for Inflammatory Disease, Monash University, Melbourne, VIC, Australia eric.morand@monash.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smolen</LastName><ForeName>Josef S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Yoshiya</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0807-7139</Identifier><AffiliationInfo><Affiliation>University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silk</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meszaros</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Torre</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Issa</LastName><ForeName>Maher</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>TechData Service, King of Prussia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xf6;rner</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6478-7725</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Charite Universit&#xe4;tsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deutsches Rheumaforschungszentrum, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>ISP4442I3Y</RegistryNumber><NameOfSubstance UI="C000596027">baricitinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">immune system diseases</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList><CoiStatement>Competing interests: EM has been on speaker bureaus for, has been a consultant for, and or received grant/research support from: AbbVie, Amgen, Asahi Kasei Pharma, AstraZeneca, Biogen, Bristol Myers Squibb, Capella Therapeutics, Eli Lilly and Company, EMD Serono, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Novartis, Sanofi, Servier, UCB Pharma, and Wolf Bio. JSS received grants to his institution from Abbvie, AstraZeneca, Lilly and Novatis and provided expert advice for, or had symposia speaking engagements with, AbbVie, Amgen, AstraZeneca, Astro, Biogen, Bristol Myers Squibb, Celgene, Celltrion, Chugai, Gilead, Janssen, Lilly, Merck Sharp &amp; Dohme, Novartis-Sandoz, Pfizer, R-Pharma, Roche, Samsung, Sanofi, and UCB. MP has been a consultant for and received grant/research support from: Eli Lilly and Company. TD has been on speaker bureaus for, has been a consultant for, and/or received grant/research support from: AbbVie, BMS, Eli Lilly and Company, Janssen, Novartis, Roche, Samsung, Sanofi, and UCB Pharma; YT has been on speaker bureaus for, has been a consultant for, and/or received grant/research support from: AbbVie, Amgen, Astellas, AstraZeneca, AYUMI Pharmaceutical, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Mitsubishi Tanabe, Sanofi, Taisho, and YL Biologics. YT has been on speaker bureaus for, has been a consultant for, and/or received grant/research support from: AbbVie, Amgen, Astellas, AstraZeneca, AYUMI Pharmaceutical, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Mitsubishi Tanabe, Sanofi, Taisho, and YL Biologics. MS, CD, GM, IdlT and MI are employees and shareholders of Eli Lilly and Company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37604638</ArticleId><ArticleId IdType="pmc">PMC10445377</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-003302</ArticleId><ArticleId IdType="pii">rmdopen-2023-003302</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fava A, Petri M. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun 2019;96:1&#x2013;13. 10.1016/j.jaut.2018.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Costa Reis P, et al. . New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 2016;12:716&#x2013;30. 10.1038/nrrheum.2016.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Croca S, Rahman A. Atherosclerosis in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2017;31:364&#x2013;72. 10.1016/j.berh.2017.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2017.09.012</ArticleId><ArticleId IdType="pubmed">29224678</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada T, Fujimori D, Yamamoto Y. Systemic lupus erythematosus and immunodeficiency. Immunol Med 2019;42:1&#x2013;9. 10.1080/25785826.2019.1628466</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/25785826.2019.1628466</ArticleId><ArticleId IdType="pubmed">31204893</ArticleId></ArticleIdList></Reference><Reference><Citation>Larosa M, Zen M, Gatto M, et al. . IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. Exp Biol Med (Maywood) 2019;244:42&#x2013;51. 10.1177/1535370218824547</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370218824547</ArticleId><ArticleId IdType="pmc">PMC6362534</ArticleId><ArticleId IdType="pubmed">30664357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahren-Herlenius M, D&#xf6;rner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013;382:819&#x2013;31. 10.1016/S0140-6736(13)60954-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)60954-X</ArticleId><ArticleId IdType="pubmed">23993191</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman RW, Merrill JT, Alarc&#xf3;n-Riquelme MME, et al. . Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab. Arthritis Rheumatol 2017;69:643&#x2013;54. 10.1002/art.39950</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39950</ArticleId><ArticleId IdType="pmc">PMC6585752</ArticleId><ArticleId IdType="pubmed">27723281</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz DM, Kanno Y, Villarino A, et al. . JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;17:78. 10.1038/nrd.2017.267</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.267</ArticleId><ArticleId IdType="pmc">PMC6168198</ArticleId><ArticleId IdType="pubmed">29282366</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, van Vollenhoven RF, Doria A, et al. . Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Res Ther 2022;24:112. 10.1186/s13075-022-02794-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02794-x</ArticleId><ArticleId IdType="pmc">PMC9109322</ArticleId><ArticleId IdType="pubmed">35578304</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Tanaka Y, Petri MA, et al. . Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial Implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med 2020;7:e000424. 10.1136/lupus-2020-000424</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000424</ArticleId><ArticleId IdType="pmc">PMC7549481</ArticleId><ArticleId IdType="pubmed">33037080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Furie RA, Tanaka Y, et al. . Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018;392:222&#x2013;31. 10.1016/S0140-6736(18)31363-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31363-1</ArticleId><ArticleId IdType="pubmed">30043749</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Vital EM, Petri M, et al. . Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 2023;401:1011&#x2013;10. 10.1016/S0140-6736(22)02607-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02607-1</ArticleId><ArticleId IdType="pubmed">36848918</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Bruce IN, D&#xf6;rner T, et al. . Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 2023;401:1011&#x2013;9. 10.1016/S0140-6736(22)02546-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02546-6</ArticleId><ArticleId IdType="pubmed">36848919</ArticleId></ArticleIdList></Reference><Reference><Citation>Illescas-Montes R, Corona-Castro CC, Melguizo-Rodr&#xed;guez L, et al. . Infectious processes and systemic lupus erythematosus. Immunology 2019;158:153&#x2013;60. 10.1111/imm.13103</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13103</ArticleId><ArticleId IdType="pmc">PMC6797874</ArticleId><ArticleId IdType="pubmed">31386190</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyrpasopoulou A, Chatzimichailidou S, Aslanidis S. Vascular disease in systemic lupus erythematosus. Autoimmune Dis 2012;2012:876456. 10.1155/2012/876456</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/876456</ArticleId><ArticleId IdType="pmc">PMC3432322</ArticleId><ArticleId IdType="pubmed">22957213</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity 2005;38:473&#x2013;85. 10.1080/08916930500285352</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930500285352</ArticleId><ArticleId IdType="pubmed">16373252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Baber N. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Br J Clin Pharmacol 1994;37:401&#x2013;4. 10.1111/j.1365-2125.1994.tb05705.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1994.tb05705.x</ArticleId><ArticleId IdType="pmc">PMC1364893</ArticleId><ArticleId IdType="pubmed">8054244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieber T, Feist E, Irvine AD, et al. . A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther 2022;39:4910&#x2013;60. 10.1007/s12325-022-02281-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-022-02281-4</ArticleId><ArticleId IdType="pmc">PMC9443639</ArticleId><ArticleId IdType="pubmed">36063279</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman MJ, Crow MK, Lockshin MD, et al. . Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007;56:3412&#x2013;9. 10.1002/art.22924</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22924</ArticleId><ArticleId IdType="pubmed">17907140</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Andreoli L, Scanzi F, et al. . The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 2017;76:10&#x2013;20. 10.1016/j.jaut.2016.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.10.004</ArticleId><ArticleId IdType="pubmed">27776934</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L, O&#x2019;Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 2019;393:2332&#x2013;43. 10.1016/S0140-6736(19)30237-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30237-5</ArticleId><ArticleId IdType="pubmed">31180030</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res 2021;232:13&#x2013;36. 10.1016/j.trsl.2020.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2020.12.007</ArticleId><ArticleId IdType="pmc">PMC7749645</ArticleId><ArticleId IdType="pubmed">33352298</ArticleId></ArticleIdList></Reference><Reference><Citation>Spihlman AP, Gadi N, Wu SC, et al. . COVID-19 and systemic lupus erythematosus: focus on immune response and therapeutics. Front Immunol 2020;11:589474. 10.3389/fimmu.2020.589474</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.589474</ArticleId><ArticleId IdType="pmc">PMC7661632</ArticleId><ArticleId IdType="pubmed">33193418</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PC, Takeuchi T, Burmester GR, et al. . Safety of Baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 2022;81:335&#x2013;43. 10.1136/annrheumdis-2021-221276</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221276</ArticleId><ArticleId IdType="pmc">PMC8862028</ArticleId><ArticleId IdType="pubmed">34706874</ArticleId></ArticleIdList></Reference><Reference><Citation>Pego-Reigosa JM, Nicholson L, Pooley N, et al. . The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. Rheumatology (Oxford) 2021;60:60&#x2013;72. 10.1093/rheumatology/keaa478</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa478</ArticleId><ArticleId IdType="pmc">PMC7785308</ArticleId><ArticleId IdType="pubmed">33099651</ArticleId></ArticleIdList></Reference><Reference><Citation>Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 2013;22:1286&#x2013;94. 10.1177/0961203313493032</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313493032</ArticleId><ArticleId IdType="pubmed">24098001</ArticleId></ArticleIdList></Reference><Reference><Citation>Adas MA, Alveyn E, Cook E, et al. . The infection risks of JAK inhibition. Expert Rev Clin Immunol 2022;18:253&#x2013;61. 10.1080/1744666X.2022.2014323</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2014323</ArticleId><ArticleId IdType="pmc">PMC8935945</ArticleId><ArticleId IdType="pubmed">34860621</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischmann R. Recent issues in JAK inhibitor safety: perspective for the clinician. Expert Rev Clin Immunol 2022;18:295&#x2013;307. 10.1080/1744666X.2022.2039122</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2039122</ArticleId><ArticleId IdType="pubmed">35129025</ArticleId></ArticleIdList></Reference><Reference><Citation>Przywara-Chowaniec B, Blachut D, Harpula J, et al. . Systemic lupus erythematosus, its impact on selected cardiovascular risk factors, and correlation with duration of illness: a pilot study. Cardiol Res Pract 2020;2020:7025329. 10.1155/2020/7025329</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/7025329</ArticleId><ArticleId IdType="pmc">PMC7665909</ArticleId><ArticleId IdType="pubmed">33204527</ArticleId></ArticleIdList></Reference><Reference><Citation>Avi&#xf1;a-Zubieta JA, To F, Vostretsova K, et al. . Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res (Hoboken) 2017;69:849&#x2013;56. 10.1002/acr.23018</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23018</ArticleId><ArticleId IdType="pubmed">28129475</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbhaiya M, Feldman CH, Guan H, et al. . Race/ethnicity and cardiovascular events among patients with systemic lupus erythematosus. Arthritis Rheumatol 2017;69:1823&#x2013;31. 10.1002/art.40174</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40174</ArticleId><ArticleId IdType="pmc">PMC6143392</ArticleId><ArticleId IdType="pubmed">28598016</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, Lin CL, Chang SN, et al. . Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. J Thromb Haemost 2014;12:452&#x2013;8. 10.1111/jth.12518</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12518</ArticleId><ArticleId IdType="pubmed">24472157</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-D&#xed;az J, Garc&#xed;a-Sosa I, S&#xe1;nchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol 2009;36:68&#x2013;75. 10.3899/jrheum.071244</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.071244</ArticleId><ArticleId IdType="pubmed">19012362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf HR, Hooper WC, Grosse SD, et al. . Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res 2015;135:50&#x2013;7. 10.1016/j.thromres.2014.10.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2014.10.012</ArticleId><ArticleId IdType="pmc">PMC4480419</ArticleId><ArticleId IdType="pubmed">25456001</ArticleId></ArticleIdList></Reference><Reference><Citation>Setyawan J, Azimi N, Strand V, et al. . Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019. Drug Saf 2021;44:889&#x2013;97. 10.1007/s40264-021-01082-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-021-01082-y</ArticleId><ArticleId IdType="pmc">PMC8280037</ArticleId><ArticleId IdType="pubmed">34120321</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzeni F, Popa CD, Nucera V, et al. . Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol 2022;18:233&#x2013;44. 10.1080/1744666X.2022.2039630</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2039630</ArticleId><ArticleId IdType="pubmed">35129033</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein A, Molad Y. Hematological manifestations among patients with rheumatic diseases. Acta Haematol 2021;144:403&#x2013;12. 10.1159/000511759</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000511759</ArticleId><ArticleId IdType="pubmed">33221805</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SB, van Vollenhoven RF, Winthrop KL, et al. . Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 2021;80:304&#x2013;11. 10.1136/annrheumdis-2020-218510</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218510</ArticleId><ArticleId IdType="pmc">PMC7892382</ArticleId><ArticleId IdType="pubmed">33115760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollenhaupt J, Silverfield J, Lee EB, et al. . Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:837&#x2013;52. 10.3899/jrheum.130683</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.130683</ArticleId><ArticleId IdType="pubmed">24692527</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay J, Harigai M, Rancourt J, et al. . Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open 2020;6:e001370. 10.1136/rmdopen-2020-001370</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001370</ArticleId><ArticleId IdType="pmc">PMC7722368</ArticleId><ArticleId IdType="pubmed">33028675</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>